Editorial
Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?
Abstract
Tyrosine kinase inhibitors (TKIs) is the best treatment choice for patients with epidermal growth factor receptor mutation (EGFR) (1).
